NASDAQ:TCON

TRACON Pharmaceuticals Competitors

$8.06
+0.25 (+3.20 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.80
Now: $8.06
$8.26
50-Day Range
$7.56
MA: $8.68
$9.65
52-Week Range
$1.55
Now: $8.06
$12.20
Volume384,400 shs
Average Volume448,722 shs
Market Capitalization$124.76 million
P/E RatioN/A
Dividend YieldN/A
Beta2.02

Competitors

TRACON Pharmaceuticals (NASDAQ:TCON) Vs. APTO, FRLN, AVRO, GRTS, JNCE, and OPT

Should you be buying TCON stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to TRACON Pharmaceuticals, including Aptose Biosciences (APTO), Freeline Therapeutics (FRLN), AVROBIO (AVRO), Gritstone Oncology (GRTS), Jounce Therapeutics (JNCE), and Opthea (OPT).

Aptose Biosciences (NASDAQ:APTO) and TRACON Pharmaceuticals (NASDAQ:TCON) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

Risk & Volatility

Aptose Biosciences has a beta of 1.62, indicating that its share price is 62% more volatile than the S&P 500. Comparatively, TRACON Pharmaceuticals has a beta of 2.02, indicating that its share price is 102% more volatile than the S&P 500.

Profitability

This table compares Aptose Biosciences and TRACON Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Aptose BiosciencesN/A-49.53%-46.65%
TRACON PharmaceuticalsN/A-273.66%-84.56%

Valuation and Earnings

This table compares Aptose Biosciences and TRACON Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Aptose BiosciencesN/AN/A$-26,280,000.00($0.52)-9.85
TRACON Pharmaceuticals$3 million41.59$-22,670,000.00($7.47)-1.08

TRACON Pharmaceuticals has higher revenue and earnings than Aptose Biosciences. Aptose Biosciences is trading at a lower price-to-earnings ratio than TRACON Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for Aptose Biosciences and TRACON Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Aptose Biosciences00803.00
TRACON Pharmaceuticals00403.00

Aptose Biosciences currently has a consensus price target of $11.6250, indicating a potential upside of 127.05%. TRACON Pharmaceuticals has a consensus price target of $16.6667, indicating a potential upside of 106.78%. Given Aptose Biosciences' higher possible upside, research analysts plainly believe Aptose Biosciences is more favorable than TRACON Pharmaceuticals.

Institutional and Insider Ownership

52.2% of Aptose Biosciences shares are owned by institutional investors. Comparatively, 42.0% of TRACON Pharmaceuticals shares are owned by institutional investors. 6.3% of Aptose Biosciences shares are owned by company insiders. Comparatively, 23.3% of TRACON Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Aptose Biosciences beats TRACON Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

TRACON Pharmaceuticals (NASDAQ:TCON) and Freeline Therapeutics (NASDAQ:FRLN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, profitability, institutional ownership, risk, dividends and earnings.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for TRACON Pharmaceuticals and Freeline Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TRACON Pharmaceuticals00403.00
Freeline Therapeutics01602.86

TRACON Pharmaceuticals currently has a consensus price target of $16.6667, suggesting a potential upside of 106.78%. Freeline Therapeutics has a consensus price target of $25.00, suggesting a potential upside of 101.29%. Given TRACON Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe TRACON Pharmaceuticals is more favorable than Freeline Therapeutics.

Profitability

This table compares TRACON Pharmaceuticals and Freeline Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TRACON PharmaceuticalsN/A-273.66%-84.56%
Freeline TherapeuticsN/AN/AN/A

Earnings & Valuation

This table compares TRACON Pharmaceuticals and Freeline Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TRACON Pharmaceuticals$3 million41.59$-22,670,000.00($7.47)-1.08
Freeline TherapeuticsN/AN/AN/AN/AN/A

Freeline Therapeutics has lower revenue, but higher earnings than TRACON Pharmaceuticals.

Insider & Institutional Ownership

42.0% of TRACON Pharmaceuticals shares are held by institutional investors. Comparatively, 38.5% of Freeline Therapeutics shares are held by institutional investors. 23.3% of TRACON Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

TRACON Pharmaceuticals beats Freeline Therapeutics on 5 of the 8 factors compared between the two stocks.

TRACON Pharmaceuticals (NASDAQ:TCON) and AVROBIO (NASDAQ:AVRO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, institutional ownership and valuation.

Analyst Ratings

This is a summary of current ratings and price targets for TRACON Pharmaceuticals and AVROBIO, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TRACON Pharmaceuticals00403.00
AVROBIO03502.63

TRACON Pharmaceuticals presently has a consensus target price of $16.6667, suggesting a potential upside of 106.78%. AVROBIO has a consensus target price of $26.00, suggesting a potential upside of 151.21%. Given AVROBIO's higher possible upside, analysts clearly believe AVROBIO is more favorable than TRACON Pharmaceuticals.

Risk & Volatility

TRACON Pharmaceuticals has a beta of 2.02, meaning that its stock price is 102% more volatile than the S&P 500. Comparatively, AVROBIO has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500.

Profitability

This table compares TRACON Pharmaceuticals and AVROBIO's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TRACON PharmaceuticalsN/A-273.66%-84.56%
AVROBION/A-51.33%-47.65%

Earnings & Valuation

This table compares TRACON Pharmaceuticals and AVROBIO's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TRACON Pharmaceuticals$3 million41.59$-22,670,000.00($7.47)-1.08
AVROBION/AN/A$-72,960,000.00($2.66)-3.89

TRACON Pharmaceuticals has higher revenue and earnings than AVROBIO. AVROBIO is trading at a lower price-to-earnings ratio than TRACON Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

42.0% of TRACON Pharmaceuticals shares are owned by institutional investors. Comparatively, 86.7% of AVROBIO shares are owned by institutional investors. 23.3% of TRACON Pharmaceuticals shares are owned by company insiders. Comparatively, 4.8% of AVROBIO shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

TRACON Pharmaceuticals (NASDAQ:TCON) and Gritstone Oncology (NASDAQ:GRTS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, institutional ownership, dividends and earnings.

Risk and Volatility

TRACON Pharmaceuticals has a beta of 2.02, suggesting that its share price is 102% more volatile than the S&P 500. Comparatively, Gritstone Oncology has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for TRACON Pharmaceuticals and Gritstone Oncology, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TRACON Pharmaceuticals00403.00
Gritstone Oncology10202.33

TRACON Pharmaceuticals presently has a consensus target price of $16.6667, indicating a potential upside of 106.78%. Gritstone Oncology has a consensus target price of $22.3333, indicating a potential upside of 158.49%. Given Gritstone Oncology's higher probable upside, analysts plainly believe Gritstone Oncology is more favorable than TRACON Pharmaceuticals.

Profitability

This table compares TRACON Pharmaceuticals and Gritstone Oncology's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TRACON PharmaceuticalsN/A-273.66%-84.56%
Gritstone Oncology-2,962.52%-101.31%-68.78%

Valuation & Earnings

This table compares TRACON Pharmaceuticals and Gritstone Oncology's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TRACON Pharmaceuticals$3 million41.59$-22,670,000.00($7.47)-1.08
Gritstone Oncology$4.36 million97.01$-94,430,000.00($2.81)-3.07

TRACON Pharmaceuticals has higher earnings, but lower revenue than Gritstone Oncology. Gritstone Oncology is trading at a lower price-to-earnings ratio than TRACON Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

42.0% of TRACON Pharmaceuticals shares are held by institutional investors. Comparatively, 59.0% of Gritstone Oncology shares are held by institutional investors. 23.3% of TRACON Pharmaceuticals shares are held by company insiders. Comparatively, 38.0% of Gritstone Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Gritstone Oncology beats TRACON Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

TRACON Pharmaceuticals (NASDAQ:TCON) and Jounce Therapeutics (NASDAQ:JNCE) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, institutional ownership, earnings, profitability and dividends.

Profitability

This table compares TRACON Pharmaceuticals and Jounce Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TRACON PharmaceuticalsN/A-273.66%-84.56%
Jounce TherapeuticsN/A-72.91%-59.68%

Earnings & Valuation

This table compares TRACON Pharmaceuticals and Jounce Therapeutics' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TRACON Pharmaceuticals$3 million41.59$-22,670,000.00($7.47)-1.08
Jounce Therapeutics$147.87 million2.79$56.82 million$1.665.48

Jounce Therapeutics has higher revenue and earnings than TRACON Pharmaceuticals. TRACON Pharmaceuticals is trading at a lower price-to-earnings ratio than Jounce Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for TRACON Pharmaceuticals and Jounce Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TRACON Pharmaceuticals00403.00
Jounce Therapeutics11402.50

TRACON Pharmaceuticals presently has a consensus target price of $16.6667, indicating a potential upside of 106.78%. Jounce Therapeutics has a consensus target price of $15.50, indicating a potential upside of 70.52%. Given TRACON Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe TRACON Pharmaceuticals is more favorable than Jounce Therapeutics.

Institutional and Insider Ownership

42.0% of TRACON Pharmaceuticals shares are owned by institutional investors. Comparatively, 60.5% of Jounce Therapeutics shares are owned by institutional investors. 23.3% of TRACON Pharmaceuticals shares are owned by insiders. Comparatively, 44.0% of Jounce Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk & Volatility

TRACON Pharmaceuticals has a beta of 2.02, indicating that its share price is 102% more volatile than the S&P 500. Comparatively, Jounce Therapeutics has a beta of 1.34, indicating that its share price is 34% more volatile than the S&P 500.

Summary

Jounce Therapeutics beats TRACON Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

TRACON Pharmaceuticals (NASDAQ:TCON) and Opthea (NASDAQ:OPT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.

Earnings and Valuation

This table compares TRACON Pharmaceuticals and Opthea's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TRACON Pharmaceuticals$3 million41.59$-22,670,000.00($7.47)-1.08
OptheaN/AN/AN/AN/AN/A

Opthea has lower revenue, but higher earnings than TRACON Pharmaceuticals.

Insider & Institutional Ownership

42.0% of TRACON Pharmaceuticals shares are held by institutional investors. 23.3% of TRACON Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for TRACON Pharmaceuticals and Opthea, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
TRACON Pharmaceuticals00403.00
Opthea01502.83

TRACON Pharmaceuticals presently has a consensus price target of $16.6667, suggesting a potential upside of 106.78%. Opthea has a consensus price target of $36.00, suggesting a potential upside of 295.60%. Given Opthea's higher possible upside, analysts plainly believe Opthea is more favorable than TRACON Pharmaceuticals.

Profitability

This table compares TRACON Pharmaceuticals and Opthea's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
TRACON PharmaceuticalsN/A-273.66%-84.56%
OptheaN/AN/AN/A


TRACON Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Aptose Biosciences logo
APTO
Aptose Biosciences
1.4$5.12+7.0%$454.86 millionN/A-8.00Increase in Short Interest
Freeline Therapeutics logo
FRLN
Freeline Therapeutics
1.6$12.42+2.3%$445.32 millionN/A0.00Analyst Report
News Coverage
AVROBIO logo
AVRO
AVROBIO
1.7$10.35+11.1%$430.79 millionN/A-3.14Analyst Upgrade
News Coverage
Gap Down
Gritstone Oncology logo
GRTS
Gritstone Oncology
1.6$8.64+2.4%$422.95 million$4.36 million-3.02
Jounce Therapeutics logo
JNCE
Jounce Therapeutics
1.6$9.09+6.8%$412.63 million$147.87 million-3.02News Coverage
Opthea logo
OPT
Opthea
1.5$9.10+0.4%$395.46 millionN/A0.00Lockup Expiration
Gap Down
SQZ Biotechnologies logo
SQZ
SQZ Biotechnologies
1.7$12.70+0.1%$353.95 millionN/A0.00
Fusion Pharmaceuticals logo
FUSN
Fusion Pharmaceuticals
1.5$8.44+3.2%$353.17 millionN/A0.00Analyst Report
Gap Down
Innate Pharma logo
IPHA
Innate Pharma
1.1$4.40+0.0%$347.56 million$96.12 million-12.94
Outlook Therapeutics logo
OTLK
Outlook Therapeutics
1.6$1.82+4.4%$315.96 million$8.15 million-1.46Increase in Short Interest
Gap Down
Cardiff Oncology logo
CRDF
Cardiff Oncology
2.0$8.28+6.0%$310.93 million$250,000.00-2.96
Surface Oncology logo
SURF
Surface Oncology
1.4$6.79+5.4%$283.33 million$15.36 million-10.29
Codiak BioSciences logo
CDAK
Codiak BioSciences
2.0$12.88+3.3%$283.28 millionN/A0.00Analyst Report
Increase in Short Interest
Eiger BioPharmaceuticals logo
EIGR
Eiger BioPharmaceuticals
1.8$8.30+1.2%$281.38 millionN/A-3.42
Autolus Therapeutics logo
AUTL
Autolus Therapeutics
1.3$5.29+4.7%$276.91 million$2.91 million-1.84
Cabaletta Bio logo
CABA
Cabaletta Bio
1.6$10.70+0.5%$257.47 millionN/A-7.81
CASI Pharmaceuticals logo
CASI
CASI Pharmaceuticals
1.7$1.79+1.1%$250.24 million$4.13 million-3.98
INmune Bio logo
INMB
INmune Bio
1.5$13.62+20.9%$203.39 millionN/A-14.04High Trading Volume
News Coverage
Gap Up
ADMA Biologics logo
ADMA
ADMA Biologics
1.6$1.65+4.8%$200.10 million$29.35 million-1.92
LogicBio Therapeutics logo
LOGC
LogicBio Therapeutics
1.3$5.88+5.8%$188.31 millionN/A-3.67
Gamida Cell logo
GMDA
Gamida Cell
1.4$7.65+2.2%$185.28 millionN/A-5.35News Coverage
Genfit logo
GNFT
Genfit
1.3$4.31+2.6%$180.70 million$45.88 million-2.19News Coverage
Protara Therapeutics logo
TARA
Protara Therapeutics
1.8$15.82+1.4%$177.64 millionN/A0.00Increase in Short Interest
News Coverage
Voyager Therapeutics logo
VYGR
Voyager Therapeutics
1.7$4.56+3.5%$171.70 million$104.39 million-2.78Gap Down
Applied Genetic Technologies logo
AGTC
Applied Genetic Technologies
1.5$3.99+1.3%$170.58 million$2.45 million-1.87Gap Up
Fennec Pharmaceuticals logo
FENC
Fennec Pharmaceuticals
1.5$6.27+2.6%$163.04 millionN/A-7.65Gap Down
Axcella Health logo
AXLA
Axcella Health
1.6$4.25+0.2%$160.18 millionN/A-1.98News Coverage
X4 Pharmaceuticals logo
XFOR
X4 Pharmaceuticals
1.8$9.01+3.2%$156.63 millionN/A-2.82News Coverage
Gap Up
Champions Oncology logo
CSBR
Champions Oncology
1.8$11.06+2.1%$148.09 million$32.12 million-85.08Analyst Upgrade
News Coverage
Gap Down
ERYTECH Pharma logo
ERYP
ERYTECH Pharma
0.5$6.91+3.6%$146.40 millionN/A-1.76News Coverage
Gap Up
Checkmate Pharmaceuticals logo
CMPI
Checkmate Pharmaceuticals
2.0$6.67+5.8%$144.19 millionN/A0.00Increase in Short Interest
News Coverage
Dyadic International logo
DYAI
Dyadic International
1.3$5.01+1.6%$138.05 million$1.68 million-14.74Increase in Short Interest
Gap Down
Pluristem Therapeutics logo
PSTI
Pluristem Therapeutics
1.4$4.34+0.0%$137.75 million$20,000.000.00News Coverage
Ayala Pharmaceuticals logo
AYLA
Ayala Pharmaceuticals
1.4$10.45+0.5%$137.63 million$2.33 million0.00Gap Down
Aziyo Biologics logo
AZYO
Aziyo Biologics
1.4$12.90+0.6%$131.92 millionN/A0.00Gap Down
Genocea Biosciences logo
GNCA
Genocea Biosciences
1.6$2.21+4.5%$118.28 millionN/A-1.52Analyst Report
Brainstorm Cell Therapeutics logo
BCLI
Brainstorm Cell Therapeutics
1.3$3.13+2.6%$111.81 millionN/A-2.98
La Jolla Pharmaceutical logo
LJPC
La Jolla Pharmaceutical
1.7$4.07+2.7%$111.63 million$23.05 million-1.81Gap Down
PolarityTE logo
PTE
PolarityTE
1.4$0.88+2.7%$106.45 million$5.65 million-0.53Increase in Short Interest
Gap Down
Cidara Therapeutics logo
CDTX
Cidara Therapeutics
1.6$2.14+1.9%$102.81 million$20.92 million-1.23
AIM ImmunoTech logo
AIM
AIM ImmunoTech
1.7$2.10+0.5%$100.43 million$140,000.000.00
Kiromic BioPharma logo
KRBP
Kiromic BioPharma
1.0$9.34+0.5%$68.49 millionN/A0.00Lockup Expiration
News Coverage
BioCardia logo
BCDA
BioCardia
1.5$3.98+3.5%$65.03 million$710,000.00-2.05Analyst Downgrade
Increase in Short Interest
Allena Pharmaceuticals logo
ALNA
Allena Pharmaceuticals
1.3$1.12+1.8%$63.77 millionN/A-0.89Gap Up
aTyr Pharma logo
LIFE
aTyr Pharma
1.5$3.77+1.9%$60.36 million$420,000.00-1.42Increase in Short Interest
News Coverage
Organovo logo
ONVO
Organovo
0.7$8.41+3.7%$59.85 million$2.20 million0.00News Coverage
Gap Down
Genetic Technologies logo
GENE
Genetic Technologies
0.4$3.87+0.8%$58.16 million$10,000.000.00Gap Down
Brickell Biotech logo
BBI
Brickell Biotech
1.5$0.84+0.5%$56.50 million$7.92 million-0.35News Coverage
Windtree Therapeutics logo
WINT
Windtree Therapeutics
2.3$2.14+1.9%$56.19 million$200,000.00-0.89Decrease in Short Interest
News Coverage
Microbot Medical logo
MBOT
Microbot Medical
1.3$7.55+2.3%$53.67 millionN/A0.00Decrease in Short Interest
Gap Down
This page was last updated on 4/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.